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Background: HIV-positive women receiving efavirenz-based ART and levonorgestrel contraceptive implants are
15 at risk of low levonorgestrel exposure and unintended pregnancy.
Objectives: To investigate clinically applicable dose-adjustment strategies to overcome the known drug–drug
interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK)
modelling-based approach.
Methods: A PBPK model was qualified against clinical data to predict levonorgestrel plasma concentrations
20 when standard-dose (150 mg) levonorgestrel implants were administered alone (control group), as well
as when standard-dose or increased-dose (300 mg) levonorgestrel implants were coadministered with either
600 or 400 mg of efavirenz.
Results: No difference was seen between in vivo clinical and PBPK-model-simulated levonorgestrel plasma con-
centrations (P.0.05). Simulated levonorgestrel plasma concentrations were 50% lower at 48 weeks post-
25 implant-placement in virtual individuals receiving standard-dose levonorgestrel with either 600 or 400 mg of
efavirenz compared with the control group (efavirenz:control geometric mean ratio"0.42 and 0.49, respec-
tively). Conversely, increased-dose levonorgestrel in combination with either 600 or 400 mg of efavirenz was suf-
ficient to restore levonorgestrel concentrations to levels similar to those observed in the 150 mg levonorgestrel
control group 48 weeks post-implant-placement (efavirenz:control geometric mean ratio"0.86 and 1.03,
30 respectively).
Conclusions: These results suggest that the clinically significant DDI between efavirenz and levonorgestrel is
likely to persist despite efavirenz dose reduction, whereas dose escalation of implantable levonorgestrel may
represent a successful clinical strategy to circumvent efavirenz–levonorgestrel DDIs and will be of use to inform
clinical trial design to assess coadministration of efavirenz and levonorgestrel implants.
35 Introduction
Long-acting reversible contraception (LARC) methods such as sub-
dermal hormonal implants offer a reversible, yet highly effective,
means of long-term pregnancy prevention,1 which can decrease
mother and child morbidity and mortality,2 especially in low- and
40 middle-income countries (LMICs), where 99% of maternal mortal-
ity occurs.3 The importance of family planning and access to LARC
is especially vital for women living in countries where the burden of
HIV is high. Worldwide, an estimated 17.8 million women aged
15 years or above were living with HIV in 2015,4 of which 95%
45resided in LMICs.4 In women living with HIV, effective contracep-
tion can decrease mother-to-child HIV transmission,5 as well as
pregnancy-related complications;6 however, countries with the
highest prevalence of HIV worldwide also exhibit the lowest use of
contraception.7 The WHO recommends progestin-containing
50implants, such as the levonorgestrel implant system (JadelleV
R
),
as a preferred method of LARC for HIV-positive women.8–10
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The levonorgestrel implant system consists of two sealed silastic
tubes, each containing 75 mg of levonorgestrel.11
Drug–drug interactions (DDIs) between antiretroviral (ARV) drugs
and hormonal contraceptives, including implants, have been
5 reported.12–17 Importantly, although efavirenz-based ART remains
the preferred first-line regimen for treatment-naive patients in
LMICs,9 it has recently been concluded that efavirenz-based ART
gives rise to the most clinically significant DDIs between ARVs and
hormone-based contraceptives.15 Indeed, Carten et al.18 reported
10 that coadministering efavirenz decreased the exposure of orally
administered levonorgestrel emergency contraception by 56%.
Furthermore, Scarsi et al.13 showed that administering efavirenz-
based ART in women whom were also using levonorgestrel-
releasing implants caused a 47% reduction in levonorgestrel
15 plasma concentrations, resulting in unintended pregnancies in 3 of
20 participants. These pharmacokinetic data also support retro-
spective clinical evaluations that demonstrated higher rates of con-
traceptive failure in women using progestin-releasing implants with
efavirenz compared with HIV-positive women receiving other or no
20 ARVs.19,20 The most recent WHO guidelines for HIV treatment
include an option to use a reduced dose of efavirenz (400 mg) as an
alternative regimen to the standard dose of efavirenz (600 mg),
once daily,9 based upon non-inferior virological outcomes and fewer
adverse events with reduced-dose efavirenz.9,21 Nevertheless, the
25 effect of reduced-dose efavirenz on the magnitude of change in
efavirenz-related DDIs, including the interaction with levonorges-
trel, has not been elucidated.
Despite the clinical importance of understanding potential
ARV–LARC DDIs, information regarding such interactions is rela-
30 tively sparse.12 Over recent years, physiologically based pharma-
cokinetic (PBPK) modelling has been increasingly used to simulate
and predict drug pharmacokinetics through the comprehensive
integration of experimental data into a mathematical description
of the processes regulating drug distribution.22,23 This computa-
35 tional approach can simulate variability in drug exposure, facilitat-
ing prospective evaluation of DDIs and prediction of likely clinical
outcomes.24,25 Conducting prospective PBPK model-based investi-
gations into the likely outcome of coadministering various drugs
can aid clinical trial design, allowing better-informed choices when
40 identifying the trials that are most likely to yield clinically beneficial
outcomes, as well as potentially reducing the number of patients
to be included in future studies.26 Furthermore, PBPK modelling is
now recognized by regulatory agencies as a method to predict
DDIs and optimize dose selection during clinical investigations.23,24
45 The aim of this study was to investigate clinically applicable
strategies to overcome the known DDI between levonorgestrel
implants and efavirenz-based ART using a PBPK modelling-based
approach. To this end, the following objectives were set. First, to
use existing in vitro and clinical data to inform a PBPK model
50 designed to predict DDIs between levonorgestrel and efavirenz,
and to qualify this model by comparing the results generated
with existing clinical data evaluating efavirenz–levonorgestrel
DDIs in HIV-infected women over 48 weeks. Second, to utilize a
qualified PBPK model to predict the effects of decreasing the dose
55 of efavirenz from 600 to 400 mg once daily on levonorgestrel
plasma concentrations when coadministered with standard-
dose levonorgestrel implants (150 mg; 2%75 mg rods). Third,
to use a qualified efavirenz–levonorgestrel PBPK model to
evaluate whether increasing the levonorgestrel implant dose
60from 150 to 300 mg (4%75 mg rods) may overcome the
efavirenz–levonorgestrel DDI.
Methods
Design of a PBPK model to predict efavirenz and
levonorgestrel interactions
65The PBPK model used in this study was designed using SimbiologyV
R
version
4.3.1, a product of MATLABV
R
version 8.2 (MathWorks, Natick, MA, USA), and
was based on a previously described qualified model, which had been used
to describe virtual DDIs between efavirenz and other drugs.27 The physico-
chemical and metabolic characteristics of simulated drugs used in this
70PBPK model are provided in Table 1.
Virtual individuals used in PBPK simulations
Virtual individuals were created using the population physiology model
physB,28 for use in efavirenz–levonorgestrel PBPK simulations. The physB
model provided a statistical description of physiological parameters repre-
75sentative of interindividual variability observed within the general female
adult population (age range 18–60 years, mean age 36.5+13 years).28
The parameters of age, height, weight, BMI and body surface area were
used to allometrically scale organ weights and tissue weights. Blood circu-
latory values accounted for variations in cardiac output and differential
80blood flow to the organs, as previously described.28
Oral absorption of efavirenz
The oral absorption of efavirenz was simulated using a compartmental
absorption and transit model, with transit times of 30 min and 3.3 h in the
Table 1. Physicochemical and metabolic characteristics of efavirenz and
levonorgestrel used in the PBPK model
Parameter Efavirenz Levonorgestrel Reference
Molecular mass (g/mol) 315.68 312.45 —
logPo:w 4.6 NA
27
pKa 10.2 NA
27
fu 0.015 NA
27
B/P 0.74 NA 27
Papp (cm/s) 2.5%10
#6 NA 30
Release rate (lg/day) NA 100 (month 1),
40 (months
2–12)
11
Volume of distribution (L/kg) NA 1.8+0.8 52
Clearance (L/h) NA 7.06+2.69 53
CYP1A2 CLint (lL/min/pmol) 0.07 NA
36
CYP2A6 CLint (lL/min/pmol) 0.08 NA
36
CYP3A4 CLint (lL/min/pmol) 0.007 NA
36
CYP2B6 CLint (lL/min/pmol) 0.55 NA
36
CYP3A4 Indmax (fold) 6.3 NA
30
CYP3A4 IndC50 (lM) 3.9 NA
30
logPo:w, logarithm of the octanol–water partition coefficient; pKa, acid
dissociation constant; fu, fraction of unbound drug in plasma; B/P, blood
to plasma ratio; Papp, apparent permeability; CYP, cytochrome P450;
CLint, intrinsic clearance; Indmax, maximal induction; IndC50, inducer con-
centration that supports half-maximal induction; NA, parameter not
applicable to the development of the current model.
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stomach and small intestine, respectively, as reported previously.29 The effec-
tive permeability (Peff) of efavirenz in Caco-2 cells
30 was used to derive the
absorption rate constant (ka) of efavirenz, as described previously.
31
Subcutaneous release rate of levonorgestrel
5 In the PBPK model, the subcutaneous release rate of levonorgestrel from
150 mg levonorgestrel implants (2%75 mg rods), was set at 100lg/day for
the first month and 40lg/day from the second month through month 12
to reflect the reported release rate of levonorgestrel from standard-dose
levonorgestrel implants in humans in vivo (Table 1).11
10 Hepatic metabolism of efavirenz and levonorgestrel
The contribution of individual hepatic cytochrome P450 (CYP) enzymes to
the total intrinsic clearance (TotCLint) of efavirenz was calculated by consid-
ering the in vitro intrinsic clearance (CLint) of efavirenz, the abundance of
each CYP enzyme in 1 mg of microsomal protein per g of liver and the liver
15 weight, as described previously.32 The systemic clearance of levonorgestrel
was derived from a previously published value53 (see Table 1), with the
metabolism of levonorgestrel assumed to be mediated by CYP3A4.11
Integration of efavirenz-mediated induction [Equation (1)] and inhibi-
tion [Equation (2)] of hepatic metabolic enzyme activity in the calculation
20 of TotCLint was achieved as follows:
Induction ¼ 1 þ ½ðEmax  IhÞ=ðEC50 þ IhÞ (1)
Inhibition ¼ 1 þ ðIh=KiÞ (2)
where: Emax"maximum induction of metabolic enzyme activity (net maxi-
mum fold-increase); EC50" concentration of inducer producing 50% of
Emax; Ki" concentration of inhibitor producing 50% of maximum inhibition
of metabolic enzyme activity; and Ih" concentration of inducer/inhibitor
within liver tissue.
25 Thereafter, the total liver CLint (CLliver) was calculated as the sum total of
TotCLint of each hepatic CYP contributing to the clearance of efavirenz, as
previously described.31
Finally, the systemic clearance of efavirenz was determined by taking
into account the blood flow into the liver (Qh) as shown in Equation (3):
Systemic clearance ¼ ðQh  fu  CLliverÞ=ðQh þ fu  CLliverÞ (3)
where fu is the fraction of unbound drug in blood.
30 The amount of efavirenz escaping hepatic metabolism (Fh) to reach the
systemic circulation was calculated using Equation (4):
Fh ¼ ðQhÞ=ðQh þ fu  CLliverÞ (4)
Volume of distribution of efavirenz and levonorgestrel
The volume of distribution of efavirenz was simulated by calculating the
35 tissue-to-plasma partition coefficient for each organ and using previously
published equations33,34 for organ volumes, which were derived from the
physB model.28 The volume of distribution of levonorgestrel was derived
from a previously reported value52 (see Table 1).
Design of parameters for efavirenz and levonorgestrel
40 metabolism
Efavirenz induces the activity of CYP3A4 in a dose-dependent manner,35 whilst
levonorgestrel is reported to undergo metabolism mainly by CYP3A4.11 The
PBPK model used herein was developed using in vitro values obtained from
published literature (Table 1).11 Efavirenz-mediated induction of CYP3A4
45activity was qualified by measuring the simulated effects of coadministering
efavirenz on the CYP3A4 substrate maraviroc, as described previously.27
Efavirenz is primarily metabolized by CYP2B6;36 however, polymorphisms in
the CYP2B6 gene, including CYP2B6 c0.516G.T, are known to result in differen-
tial metabolism of efavirenz.37,38 Given that this polymorphism affects efavir-
50enz disposition and has been shown to impact levonorgestrel metabolism,39
the PBPK model was designed to reflect the genotypic frequency of CYP2B6
genotypes 516GG, 516GT and 516TT as 0.45, 0.43 and 0.12, respectively,
typical of the genotypic frequency observed in an African population.40
Design of virtual DDI studies
55PBPK model simulations of efavirenz–levonorgestrel coadministration were
performed in 100 virtual individuals receiving either 400 or 600 mg of efavir-
enz once daily in combination with either 150 mg of implantable levonorges-
trel (2%75 mg rods) or 300 mg of implantable levonorgestrel (4%75 mg rods)
for the duration of the study. The simulated steady-state plasma concentra-
60tion (Css) of levonorgestrel and efavirenz was measured at 1, 4, 12, 24, 36 and
48 weeks after virtual placement of the levonorgestrel implant system(s) for
each dosing strategy, to facilitate comparison with a recent clinical study.13
In addition, the effect of increased-dose implantable levonorgestrel (300 mg)
on the efavirenz–levonorgestrel DDI was simulated in multiple groups of 25
65patients to evaluate the potential effects of smaller sample sizes, akin to the
numbers of individuals observed in previous13 and current (NCT02722421)41
clinical trials on pharmacokinetic variability in this specific context.
Qualification of the efavirenz–levonorgestrel PBPK
model and comparison of simulated pharmacokinetics
70with clinical data
In order to qualify the efavirenz–levonorgestrel PBPK model, efavirenz and
levonorgestrel concentrations observed in a clinical study reported by
Scarsi et al.13 were compared with PBPK model-simulated pharmacoki-
netics of both efavirenz and levonorgestrel to evaluate potential differences
75between PBPK-computed predictive values and observed clinical data. The
geometric mean and 90% CI for log10-transformed plasma concentrations
of levonorgestrel and efavirenz at weeks 12 and 24 (representative of
steady-state conditions) in 100 virtual individuals were calculated and eval-
uated against data obtained in vivo13 by a parametric t-test. To evaluate
80potential discrepancies between the simulated and observed DDI, the rela-
tionship between log10 levonorgestrel and efavirenz exposure was investi-
gated using linear regression analysis (significance threshold P,0.2,
a"0.05). To compare the effects of 600 and 400 mg of efavirenz on levo-
norgestrel exposure, the geometric mean ratio (GMR) and 90% CI between
85each efavirenz group and the control group [standard-dose (150 mg) levo-
norgestrel implants without efavirenz] was calculated. A GMR between
0.8 and 1.25 represented bioequivalent pharmacokinetic exposure.42,43
Statistical analysis
Statistical analyses were carried out using IBMV
R
SPSSV
R
Statistics (version 22;
90IBM Corporation, Armonk, NY, USA). Graphs were drawn using GraphPad Prism
software (version 5; GraphPad Software, Inc., La Jolla, CA, USA). Geometric
means were compared using an independent samples non-parametric t-test,
in which P values0.05 were considered statistically significant.
Results
95Qualification of the efavirenz–levonorgestrel PBPK
model
Box-and-whisker plot analysis revealed similar symmetry of data
distribution in both the PBPK-simulated log10 Css values
and observed in vivo clinical log10 Css values for both levonorgestrel
Dose adjustment to overcome efavirenz–levonorgestrel interactions JAC
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and efavirenz at 12 weeks (Figure 1a and c) and 24 weeks
(Figure 1b and d), respectively. At 24 weeks, median log10 levonor-
gestrel simulated and observed plasma concentrations were 2.39
and 2.43 pg/mL, respectively (Figure 1b), whilst median log10 efa-
5 virenz simulated and observed plasma concentrations at 24 weeks
were 3.39 and 3.42 ng/mL, respectively (Figure 1d).
To further examine the comparability of the observed in vivo
clinical efavirenz plasma concentrations and PBPK model-simulated
efavirenz plasma concentrations, the GMRs of simulated-to-
10 observed efavirenz plasma concentrations following administration
of 600 mg of efavirenz once daily were calculated (Table 2).
The GMRs of simulated-to-observed efavirenz plasma concentra-
tions were similar, ranging from 0.84 to 1.27 (Table 2). Statistical
analysis of PBPK-simulated and clinically observed levonorgestrel
15 and efavirenz exposures at weeks 12 and 24 showed no significant
differences (P.0.05).
Linear regression analysis also supported that the effect of efavir-
enz on levonorgestrel concentrations was similar when comparing
PBPK-simulated data and clinical data.13 Specifically, considering
20 log10 concentrations, at week 12, the constant (90% CI) was
equal to 2.685 (2.587–2.784) and b was equal to#0.395
(#0.583 to#0.207) for in vivo clinical data versus 2.538
(2.48–2.595) and#0.242 (#0.340 to#0.144) for the simulated DDI.
At week 24, the constant was equal to (90% CI) 2.657 (2.570–2.744)
25and b was equal to# 0.461 (#0.617 to#0.304) for in vivo clinical
data versus 2.527 (2.470–2.583) and #0.241 (#0.339 to#0.143)
for the simulated DDI.
Prediction of the effects of efavirenz dose reduction
from 600 to 400mg once daily on levonorgestrel
30plasma concentrations
Using the PBPK model, levonorgestrel plasma concentrations were
simulated at 1, 4, 12, 24, 36 and 48 weeks in virtual individuals
receiving 150 mg levonorgestrel implants without ART (control
group) and in virtual individuals receiving 150 mg levonorgestrel
35implants in combination with either standard-dose (600 mg) efa-
virenz or reduced-dose (400 mg) efavirenz once daily (Figure 2 and
Table 3). In virtual individuals receiving 150 mg levonorgestrel
implants without ART, the simulated levonorgestrel Css at
48 weeks was 578 pg/mL, whereas in simulated individuals receiv-
40ing 150 mg levonorgestrel implants plus 600 mg of efavirenz, the
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Figure 1. Comparison of PBPK-model-simulated plasma concentrations and clinical plasma concentrations of levonorgestrel and efavirenz. Box and
whisker plots showing log10 PBPK-model-simulated levonorgestrel plasma concentrations and observed
a levonorgestrel plasma concentrations
obtained at (a) 12 weeks and (b) 24 weeks post-implant-placement and log10 PBPK-model-simulated and observed
b efavirenz plasma concentrations
obtained at (c) 12 weeks and (d) 24 weeks after placement of the levonorgestrel implants. One hundred virtual individuals were used for the PBPK
model simulations, whilst clinical samples were collected from 20 individual patients in each case. aObserved in vivo levonorgestrel plasma concen-
trations are as published by Scarsi et al.13 bPreviously unpublished observed in vivo efavirenz plasma concentrations collected 12–14 h after efavirenz
dose.13 Whiskers"minimum and maximum values. EFV, efavirenz; LNG, levonorgestrel.
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simulated levonorgestrel Css at 48 weeks was 245 pg/mL [GMR
(90% CI) 0.42 (0.38–0.47); Table 3]. These simulated data are con-
sistent with in vivo data in HIV-infected women receiving 150 mg
levonorgestrel implants plus 600 mg of efavirenz when compared
5 with individuals receiving 150 mg levonorgestrel implants without
ART [GMR (90% CI) 0.43 (0.42–0.44)].13 In virtual individuals
receiving 150 mg levonorgestrel implants together with 400 mg of
efavirenz, the simulated levonorgestrel Css at 48 weeks was
281 pg/mL [GMR (90% CI) 0.49 (0.43–0.55); Table 3]; this repre-
10 sented a!6% (P"0.1) relative increase in simulated levonorges-
trel plasma concentrations compared with the control group when
standard-dose levonorgestrel was administered with 400 mg of
efavirenz, as opposed to when standard-dose levonorgestrel was
administered with 600 mg of efavirenz.
15Comparing the PBPK-simulated effects of increased-
dose levonorgestrel when coadministered with 600 or
400mg of efavirenz
A PBPK simulation of the effects of coadministering 600 mg of efa-
virenz with increased-dose (300 mg) levonorgestrel implants in
20100 virtual individuals yielded simulated levonorgestrel plasma
concentrations of 607 pg/mL at 1 week post-implant-placement,
gradually decreasing to 500 pg/mL at 48 weeks post-implant-
placement (Table 3 and Figure 3). Compared with the control group
(150 mg levonorgestrel implants without efavirenz), the GMR (90%
25CI) of simulated levonorgestrel concentrations from 300 mg levo-
norgestrel implants plus 600 mg of efavirenz was 0.86 (0.77–0.97)
at 48 weeks post-implant-placement (Table 3). Similar simulations
conducted in 12 groups of 25 virtual individuals resulted in geomet-
ric mean levonorgestrel plasma concentrations (90% CI) ranging
30from 516 (449–592) pg/mL to 728 (599–884) pg/mL at 1 week
post-implant-placement and ranging from 443 (375–523) pg/mL
to 591 (505–691) pg/mL at 48 weeks post-implant-placement.
When a daily dose of 400 mg of efavirenz was applied in the PBPK
model in combination with 300 mg levonorgestrel implants,
35simulated levonorgestrel plasma concentrations in 100 virtual indi-
viduals were 724 pg/mL at week 1 and 593 pg/mL at 48 weeks
post-implant-placement (Table 3 and Figure 3). Compared with the
control group, the GMR (90% CI) of simulated levonorgestrel concen-
trations from 300 mg levonorgestrel implants in combination with
40400 mg of efavirenz once daily was 1.03 (0.91–1.16) at 48 weeks
post-implant-placement (Table 3). By comparison, when PBPK simu-
lations were conducted in smaller numbers of virtual patients
(12 groups of 25 patients), coadministration of 400 mg of efavirenz
with increased-dose (300 mg) levonorgestrel implants yielded geo-
45metric mean levonorgestrel plasma concentrations (90% CI) ranging
Table 2. Comparison of in silico and in vivo efavirenz plasma
concentrations
Week
In silico-simulated
efavirenz (ng/mL)a
In vivo-observed
efavirenz (ng/mL)b
GMR simulated efavirenz:
observed efavirenzc
1 2402 (2218–2601) 2850 (2186–3718) 0.84 (0.68–1.05)
4 2931 (2605–3299) 2707 (2099–3489) 1.08 (0.81–1.45)
12 2995 (2643–3395) 2709 (2095–3503) 1.11 (0.81–1.50)
24 2998 (2644–3400) 2863 (2174–3771) 1.05 (0.77–1.43)
36 2998 (2644–3400) 2913 (2076–4087) 1.03 (0.73–1.45)
48 2998 (2644–3400) 2362 (1701–3281) 1.27 (0.92–1.76)
In vivo efavirenz plasma concentration 12–14 h post-dose was meas-
ured at 1, 4, 12, 24, 36 and 48 weeks post-insertion of a standard-dose
(150 mg) levonorgestrel implant in 20 HIV-positive women receiving
600 mg of efavirenz once daily. These data were compared with in silico
PBPK-simulated efavirenz (600 mg once daily) concentrations generated
in a similar group of 100 virtual individuals.
aData are presented as geometric means of simulated efavirenz plasma
concentrations with 90% CI calculated from 100 virtual individuals.
bData are presented as geometric means of in vivo efavirenz plasma
concentrations with 90% CI calculated from 20 HIV-positive women
(previously unpublished data collected as part of Scarsi et al.13).
cData are presented as GMRs with 90% CI.
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Figure 2. Geometric mean of PBPK-simulated standard-dose levonorgestrel plasma concentrations in 100 virtual individuals measured over
48 weeks after placement of 150 mg levonorgestrel implants in combination with standard- and reduced-dose efavirenz. The geometric mean of the
PBPK-simulated levonorgestrel plasma concentrations is shown at 1, 4, 12, 24, 36 and 48 weeks following placement of: standard-dose levonorges-
trel implants (150 mg) alone (broken line, open squares); standard-dose levonorgestrel implants together with 600 mg of efavirenz once daily (con-
tinuous line, open circles); or standard-dose levonorgestrel implants together with 400 mg of efavirenz once daily (continuous line, filled squares).
Error bars"90% CI. EFV, efavirenz; LNG, levonorgestrel.
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from 620 (532–724) pg/mL to 837 (700–1001) pg/mL at 1 week
post-implant-placement and ranging from 507 (428–600) pg/mL to
680 (557–830) pg/mL at 48 weeks post-implant-placement.
Discussion
5 Previous work demonstrated that levonorgestrel plasma concen-
trations decreased 47% when 150 mg levonorgestrel subdermal
implants were administered with efavirenz-based ART,13 which
resulted in contraceptive failure and unintended pregnancies in
some patients.13 The presented PBPK model showed that reducing
10the daily dose of efavirenz from 600 to 400 mg did not significantly
alter the efavirenz–levonorgestrel DDI (Figure 2 and Table 3), sug-
gesting that reduced-dose (400 mg) efavirenz may not fully miti-
gate the risk of contraceptive failure when combined with
standard-dose (150 mg) levonorgestrel implants. An encouraging
15finding of the present study was that an increase in levonorgestrel
dosing to 300 mg, in combination with either 600 or 400 mg of
Table 3. In silico levonorgestrel plasma concentrations measured over 48 weeks following the administration of standard- and increased-dose
levonorgestrel implants in combination with standard- and reduced-dose efavirenz
Week 1 Week 4 Week 24 Week 48
LNG 150 mg subdermal implant (standard dose)a
LNG 150 mg alone (control group) (pg/mL) 623 (579–671) 628 (581–678) 608 (563–657) 578 (535–624)
LNG 150 mg! EFV 600 mg (pg/mL) 291 (270–314) 268 (248–290) 258 (239–279) 245 (226–265)
LNG 150 mg! EFV 400 mg (pg/mL) 341 (317–368) 308 (284–334) 296 (273–321) 281 (259–305)
Standard-dose LNG GMR (90% CI) between groupsb
EFV 600 mg versus control group 0.47 (0.42–0.52) 0.43 (0.38–0.48) 0.42 (0.38–0.47) 0.42 (0.38–0.47)
EFV 400 mg versus control group 0.55 (0.49–0.61) 0.49 (0.44–0.55) 0.49 (0.43–0.55) 0.49 (0.43–0.55)
LNG 300 mg subdermal implant (increased dose)a
LNG 300 mg! EFV 600 mg (pg/mL) 607 (559–660) 547 (501–598) 527 (482–576) 500 (458–546)
LNG 300 mg! EFV 400 mg (pg/mL) 724 (664–789) 651 (594–713) 625 (569–686) 593 (541–651)
Increased-dose LNG GMR (90% CI) between groupsb
EFV 600 mg versus control group 0.97 (0.87–1.09) 0.87 (0.77–0.98) 0.87 (0.77–0.97) 0.86 (0.77–0.97)
EFV 400 mg versus control group 1.16 (1.04–1.30) 1.04 (0.92–1.17) 1.03 (0.91–1.16) 1.03 (0.91–1.16)
EFV, efavirenz; LNG, levonorgestrel.
PBPK-simulated levonorgestrel plasma concentrations generated over 48 weeks post-insertion at week 0 of levonorgestrel implants in virtual individ-
uals administered standard-dose levonorgestrel implants (150 mg) alone (control group) or with either standard-dose levonorgestrel implants
(150 mg) or increased-dose levonorgestrel implants (300 mg) in combination with either 600 mg of efavirenz once daily or 400 mg of efavirenz once
daily. One hundred virtual individuals were simulated per group. GMRs were compared between each respective combined efavirenz–levonorgestrel
group and the 150 mg levonorgestrel control group in each case.
aData are presented as geometric means of simulated levonorgestrel plasma concentrations with 90% CI.
bData are presented as GMRs with 90% CI.
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Figure 3. Geometric mean of PBPK-simulated increased-dose levonorgestrel plasma concentrations in 100 virtual individuals measured over
48 weeks after placement of 300 mg levonorgestrel implants in combination with standard- and reduced-dose efavirenz. The geometric mean of
PBPK-simulated levonorgestrel plasma concentrations is shown at 1, 4, 12, 24, 36 and 48 weeks following placement of: standard-dose levonorges-
trel implants (150 mg) alone (broken line, open squares); increased-dose levonorgestrel implants (300 mg) together with 600 mg of efavirenz once
daily (continuous line, open circles); or increased-dose levonorgestrel implants together with 400 mg of efavirenz once daily (continuous line, filled
squares). Error bars"90% CI. EFV, efavirenz; LNG, levonorgestrel.
Roberts et al.
6 of 9
efavirenz, was sufficient to raise simulated levonorgestrel
plasma concentrations within the qualified PBPK model to levels
comparable to those observed when standard-dose levonorges-
trel implants were administered alone, without efavirenz (Figure 3
5 and Table 3; GMR between 0.8 and 1.2542,43). Given the close asso-
ciation between PBPK model-simulated levonorgestrel plasma
concentrations and in vivo clinically observed levonorgestrel con-
centrations, coadministration of increased-dose (300 mg) levonor-
gestrel implants together with either 600 or 400 mg of efavirenz
10 warrants clinical investigation.
Prior work has described a dose-dependent induction of hepatic
CYP3A4 activity in human volunteers receiving efavirenz in vivo;35
furthermore, in vitro studies conducted in primary human hepato-
cytes have shown that efavirenz can induce both CYP3A4 expres-
15 sion and CYP3A4 activity in a concentration-dependent manner.44
These data suggest a hypothesis whereby a dose reduction of efa-
virenz from 600 to 400 mg may result in fewer clinically significant
DDIs with CYP3A4 substrates, such as levonorgestrel. However, the
present study showed that simulated levonorgestrel plasma con-
20 centrations were similar between simulated patients receiving
either efavirenz dose, thus suggesting that an efavirenz dose
reduction from 600 to 400 mg, may not be sufficient to overcome
efavirenz-induced DDIs with CYP3A4 substrates in vivo. It is hereby
proposed that this is likely due to the potency of efavirenz as a
25 CYP3A4 inducer, which has previously been reported to be compa-
rable, in vitro, to that of the induction potential of the well-
documented CYP3A4 inducer rifampicin.44
The present efavirenz–levonorgestrel PBPK model was
designed to take into account the known differential metabolism
30 of efavirenz as influenced by CYP2B6 polymorphisms39 to predict
the resultant effects upon levonorgestrel plasma concentrations.
Clinically observed efavirenz plasma concentrations and PBPK
model-simulated efavirenz concentrations showed a high degree
of similarity (Figure 1 and Table 2), whilst the usefulness of the
35 PBPK model as a tool to predict DDIs between levonorgestrel and
efavirenz was further exemplified by linear regression analysis,
which indicated no significant differences between the PBPK-
simulated data and published clinical data. However, simulations
conducted in a reduced number of virtual individuals, similar to the
40 patient numbers typically evaluated in clinical pharmacokinetic
evaluations,13,41 resulted in more variable simulated levonorges-
trel plasma concentrations when compared with efavirenz–
levonorgestrel DDI predictions based on 100 virtual individuals.
Taken together, it is suggested that the interindividual variability in
45 the extent of efavirenz–levonorgestrel DDI may influence clinical
pharmacokinetic evaluations of this interaction and, further, the
clinical recommendations regarding the coadministration of efa-
virenz and levonorgestrel.
Subdermal hormonal implants are among the most effective
50 methods of contraception available worldwide, with an expected
failure rate of ,1% during the first year of use.16,45 Therefore,
women choosing a contraceptive implant for family planning
expect near-perfect effectiveness, and a DDI that reduces this
effectiveness must be clearly described to patients in order to
55 allow an informed choice of contraceptive method to be made. In
recent years, an increase in the provision of implantable LARCs in
sub-Saharan Africa has occured (.9-fold between 2008 and
2012).46 With price reductions, the provision of and accessibility to
hormone-releasing implantable contraceptives in LMICs is likely to
60continue to increase over the coming years.47 Despite the recent
inclusion of dolutegravir-based ART in the WHO guidelines, efavir-
enz is expected to remain in 50% of first-line ART regimens in
LMICs for the next decade.48 Therefore, further characterization of
the DDI between efavirenz and levonorgestrel is of great impor-
65tance in the effort to prevent unintended pregnancy and mother-
to-child transmission of HIV and to improve the overall health of
women residing in LMICs.16
The presented PBPK model represents a useful strategy to aid in
predicting the likely outcome of clinical pharmacological
70approaches to overcome detrimental DDIs. However, whilst PBPK
models are increasingly accepted by drug regulatory agencies,24
cautious interpretation of the presented data is nevertheless
required, due to the fact that in vitro-to-in vivo extrapolation is
both challenging and has several limitations.49,50 With respect to
75the current PBPK model, further customization may be necessary
to reflect pharmacogenetic differences when conducting prospec-
tive efavirenz–levonorgestrel DDI studies in populations of distinct
ethnicities. In addition, the current model does not consider the
relative contribution that transporters and non-CYP metabolic
80enzymes may have in efavirenz and levonorgestrel disposition.
Finally, the potential effect of efavirenz and levonorgestrel upon
drug transporter activity in the subcutaneous tissue immediately
proximal to levonorgestrel implants is not currently known, but
may have a role in the absorption and distribution of levonorges-
85trel. In order to address these limitations, further studies aimed at
elucidating the mechanisms of levonorgestrel metabolism will be
necessary.
Given the clinical significance of DDIs that occur between
efavirenz-based ART and hormone-based contraceptives,
90future work should aim to investigate DDIs between efavirenz and
other progestin-based implants.15 For example, administering
efavirenz-based ART in women using etonogestrel implants has
been shown to reduce etonogestrel plasma concentrations by
82%.17,51 Furthermore, contraceptive failure of etonogestrel-
95releasing implants has been reported in HIV-positive women con-
currently treated with efavirenz-based ART. Therefore, developing
a similar PBPK model-based approach to that described here in
order to evaluate dose-adjustment strategies for coadministering
such implants with efavirenz or other ARVs would be warranted.
100In conclusion, this study provides insight into the extent of the
DDI between levonorgestrel and efavirenz, yielding information to
inform optimization of dosing strategies for combining efavirenz-
based ART with levonorgestrel implants. The model predicted that
levonorgestrel dose escalation in combination with either 600 or
105400 mg of efavirenz has the potential to maintain levonorgestrel
plasma concentrations (GMR between 0.8 and 1.25) compared
with women using standard-dose levonorgestrel implant without
ART;42,43 a relatively smaller virtual sample size, however, yielded
more variable findings. One clinical study investigating the effects
110of coadministering 600 mg of efavirenz in combination with
increased-dose (300 mg) levonorgestrel implants is currently
underway (NIH, NCT0272242141). Finally, this qualified in silico
model will serve as a useful basis from which other ARV–hormonal
contraceptive DDIs may be investigated.
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